Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Institutes of Health (U19 AI089992, R25 NS079193, P01 AI073748, U24 AI11867, R01 AI22220, UM 1HG009390, P01 AI039671, P50 CA121974, R01 CA227473, K08 AI128745, R01 AI162645, 5T32 AI 007019-46)
National Multiple Sclerosis Society (CA 1061- A-18, RG-1802-30153)
Nancy Taylor Foundation for Chronic Diseases
Race to Erase MS
Pew Charitable Trusts
Richard and Susan Smith Family Foundation
- License Information
-
More Information
Article History
Received: 3 December 2021
Accepted: 8 May 2022
First Online: 22 June 2022
Declarations
:
: D. A. H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. Further information regarding funding is available on
